Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2021 09:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

SEATTLE, June 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
June 09, 2021 09:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
June 07, 2021 09:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021

SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
May 14, 2021 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
May 14, 2021 09:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 11, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific Time

SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
April 30, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021

SEATTLE, April 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
April 08, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway

SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
March 31, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update

SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
March 22, 2021 08:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

SEATTLE, March 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop...